engineered cells. The cells equally activated the downstream effector Stat5, and were equally sensitive to imatinib, despite the huge differences in protein expression levels. Moreover, previous data on the mechanism of activation were confirmed in the CRISPR/Cas engineered cells. Our data demonstrate an important application of the CRISPR/Cas genome editing tool, which makes it possible to study the oncogenic properties of activated tyrosine kinases without the need for ectopic overexpression.
Alterations in genes encoding epigenetic regulators are common in myeloid malignancies, and several recent studies have demonstrated that these mutations are present at high frequencies within peripheral blood cells in~10% of individuals over 60 years of age. Although the presence of these mutations carries an increased risk of subsequent hematologic malignancies, the vast majority of individuals do not progress clinically and the natural history of clonal hematopoiesis is unclear. [1] [2] [3] Thus, the term Clonal Hematopoiesis of Indeterminate Potential (CHIP) was proposed. 4 Allogeneic bone marrow transplantation (alloBMT) remains the only curative therapy for many patients with hematologic malignancies. Over the past decade, advances in alloBMT have permitted older patients to successfully undergo the procedure. Accordingly, older matched sibling donors are being utilized. Moreover, the development of safe and effective haploidentical BMT allows parents to serve as related donors for their children. 5 We hypothesized that clinically silent 'premalignant' clones (which do not result in overt malignancy under homeostatic conditions within the donor) may be subjected to substantial proliferative and self-renewal stress during the engraftment process and could undergo transformation. We report two cases of donor cell leukemia (DCL) arising from CHIP marked by somatic mutations in leukemia-related genes in donors over age 60 years.
The study was approved by the Institutional Review Board at the Johns Hopkins University. Clonality was detected by a custom leukemia DNA sequencing panel covering 637 genes important in oncogenesis (Supplementary Methods).
From 2011 to 2014, we used 61 bone marrow donors 460 years-of-age at our institution (Supplementary Table 1 ). Median and maximum follow-up were 389 and 1481 days, respectively. Two recipients developed DCL for a cumulative incidence of 6.3% (95% confidence intervals: 0.94%, 19.6%). Donors and recipients characteristics are given in Supplementary Tables 1 and 2 . Patient 1 was diagnosed with therapy-related AML and received two rounds of induction chemotherapy followed by myeloablative, haploidentical allo-BMT from his 68-year-old mother. The patient's course was complicated by primary graft failure and he subsequently underwent salvage nonmyeloablative haploidentical peripheral blood stem cell transplantation from the same donor. The bone marrow biopsy at 2.5 years showed focal erythroid dysplasia and no increased blasts (Supplementary Figure 1a) . His routine 3-year post-BMT marrow revealed erythroid dysplasia and a rare (1%) population of abnormal myeloblasts identified by flow cytometry (Supplementary Figure 1b) . The bone marrow biopsy 1 month later revealed 430% myeloid blasts, a normal female karyotype (Supplementary Figure 1c) and full donor chimerism, consistent with DCL ( Figure 1d ).
Patient 2 was diagnosed with a stage IIIB B-cell lymphoma. The patient eventually achieved a complete remission and underwent a nonmyeloablative, haploidentical allo-BMT with eight cycles of post-BMT rituximab maintenance. Patient's 61-year-old mother was utilized as a donor. His post-transplant course was complicated by protracted late-onset neutropenia and thrombocytopenia. Bone marrow biopsy at 13 months was unremarkable (Supplementary Figure 1d) . Cytopenias persisted; repeat bone marrow biopsy 18 months post BMT showed significant erythroid dysplasia, monosomy 7 in one-third of the cells (Supplementary Figure 1e) and full donor chimerism consistent with myelodysplastic syndrome (MDS) of donor origin (Figure 1h) .
To identify the presence of clonal hematopoiesis in donors, which may have contributed to DCL, we compared nextgeneration DNA sequencing (NGS) data sets from donors and paired DCL samples in order to detect variants that expanded 43-fold from donor to DCL. Using this approach we identified low-frequency clones marked by somatic mutations in both older donors. In donor 1, two mutations affected DNMT3A were found: a missense mutation in exon 18, codon 710 (chr2:25463553C4G p.C710S, referred to as DNMT3Ae; variant allele frequency (VAF) = 0.7%) and an intronic mutation (chr2:25464428T4C, referred to as DNMT3Ai) (VAF = 1.7%). The location of the latter within the conserved splice donor site raises the possibility of aberrant splicing and altered protein function. The third mutation was found in ATM (chr11:108236198T4C, p.L3045P, VAF = 1.4%). In donor 2, three mutations were identified: a missense mutation in U2AF1 (chr21; 44514777T4G, p.Q157P; VAF = 1.3%) and EP300 (chr22; 41537062A4G, p.Y630C; VAF = 1.3%), along with a mutation in the 3ʹ untranslated region of MYH9 (chr22; 36678355T4G; VAF = 1.9%). In donor 1, clonal expansion was likely driven by alterations in the DNMT3A gene. The further dominance of one of the clones was likely facilitated by the acquisition of a cooperating ATM mutation. In donor 2, similar frequencies of the mutations suggest a close temporal acquisition of all three mutations (Figures 1e-g and Supplementary Table 3 including three mutations present in donor pre-alloBMT (Supplementary Table 3 ). Although both donor clones significantly expanded in the recipient, the VAF of the clone carrying DNMT3Ai and ATM mutations increased more than 10-fold (VAF = 17% and 16%, respectively) compared with 7-fold for the minor clone with 
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Letters to the Editor heterozygous mutations in DNMT3Ai (VAF = 17%) and ATM (VAF = 16%). The blasts appeared to have acquired an additional mutation in CBFB (VAF = 36%). Further clonal evolution was marked by acquisition of cooperating mutations involving CSF3R, S1PR2 and SETBP1 among others (Figure 2b ). The VAF of the CBFB mutation was nearly double the VAF of the DNMT3Ai/ATM clone suggesting either deletion of the wild-type CBFB or biallelic mutation. Metaphase karyotyping revealed a normal female karytope both in the donor cells before alloBMT and at DCL diagnosis. Single nucleotide polymorphism array (SNP-A) revealed acquired copy-neutral loss of heterozygosity (CN-LOH) spanning chromosome 16q, the location of CBFB (Supplementary Figure 2) . This explains the biallelic CBFB mutation and suggests it is in the same clone as the antecedent DNMT3Ai and ATM mutations. Post-alloBMT course of Patient 2 was complicated by protracted pancytopenia and bone marrow at 18 months showed significant erythroid dysplasia and monosomy 7. NGS analysis revealed seven somatic mutations including three mutations present in donor pre-alloBMT (Supplementary Table 3 ). Three mutations identified in the donor expanded more than 25-fold (Figures 1e-g and Figure 2c ). The evolution of DCL was also associated with the acquisition of cooperating mutations in GUCY1A2, CSMD3, MPL and SETBP1. Our data suggest that premalignant donor-derived clones expanded within the recipient, and acquired additional mutations causing malignant transformation (Figure 2d ). The donor origin of leukemia was confirmed by short tandem repeat polymorphism analysis (Figures 1d and h ).
DCL was first described in 1971, and for years was considered rare. 6 The pathogenesis of DCL has been unclear; some cases may have unrecognized clonal disorders in the bone marrow donors 7, 8 or inherited defects when cord blood is used. 9 The frequency of DCL appears to be steadily increasing, perhaps in part a result of routine and sensitive post-BMT chimerism testing. 10 However, the utilization of older donors who are more likely to carry clonal hematopoiesis may also account for the increase. Our study describes the molecular evolution of CHIP within the donors into DCL. Somatic mutations in MDS-associated genes like U2AF1 and DNMT3A along with ATM, MYH9 and EP300 resulted in their clonal expansion. Previous studies suggest that alterations in DNMT3A and U2AF1 are the first genetic events to arise within clonal hematopoiesis and likely represent true drivers/predisposing mutations in the oncogenic process. 11 Animal studies have shown that the loss of DNMT3A impaired differentiation and upregulation of multipotency genes in hematopoietic stem and progenitor cells (HSPC). 12 Similarly, mutated U2AF1 resulted in cytopenias and the expansion of HSPC in mice. 13 Although necessary for initial clonal expansion, these changes were insufficient for oncogenic transformation as the donors remain hematologically normal nearly 5 and 2 years since transplantation. In the recipients, the change from homeostatic to regenerative hematopoiesis after alloBMT may have driven further clonal expansion and eventually oncogenic transformation. The use of alkylating agents like posttransplant cyclophosphamide (PTCy) as graft-versus-host disease prophylaxis may have contributed to genotoxic stress and acquisition of additional mutations and structural chromosomal changes like deletion 7 or CN-LOH of 16q. However, we do not believe PTCy is necessary for the development of DCL since Patient 1 did not receive it after his second transplant, and because the incidence of DCL is similar in our cohort who received PTCy to those who did not. 5 The transformation appeared to be associated with acquisition of cooperating mutations followed by a series of subclonal events such as SETBP1 mutations that are late progression events in myeloid malignancies. 14 The acquisition of genetic abnormalities leading to clonal dominance has been demonstrated in the transformation of MDS to secondary AML. 15 Our study tracks changes from subclinical clonal hematopoiesis to malignancy and confirms the propensity of specific mutated clones to evolve to MDS and leukemia. Similar to other premalignant conditions, the latency period may span years or even decades, such that the majority of patients are unlikely to develop overt disease. This time frame may radically shorten under cell-extrinsic stress uniformly associated with the post-BMT reconstitution of donor-derived hematopoiesis. Thus, meticulous assessment of older donors beyond routine hemograms, bone marrow morphology and traditional cytogenetics should be considered. Moreover, formal studies in alloBMT patients and their donors are needed to further understand the incidence of clonal donor hematopoiesis leading to DCL. In recent years the anti-CD19/anti-CD3 bispecific antibody blinatumomab and chimeric antigen receptor (CAR) modified T cells targeting CD19 have shown early efficacy in clinical trials of paediatric and adult B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). [1] [2] [3] [4] [5] The rationale behind targeting CD19 in BCP-ALL is primarily its homogenous cell surface expression and B-lineage specificity. 5 Thus, the entire malignant cell population should be targeted and eradicated by anti-CD19-directed immunotherapies. CD19 would be expected to have important functions in BCP-ALL survival, based on its roles in enhancing pre-B-cell receptor (pre-BCR) mediated phosphoinositide 3-kinase (PI3K) signalling and through pre-BCR-independent pathways such as MYC activation. [6] [7] [8] [9] However, the effects of CD19 depletion on BCP-ALL cells have not been investigated. Hence, we examined the role of CD19 in leukaemic maintenance by silencing its expression in BCP-ALL cell lines and primograft samples using RNA interference.
First, we explored the effects of CD19 knockdown in CD19 + BCP-ALL cell lines reflecting three maturation stages of BCP-ALL: pro-B-ALL SEM (CD10 . BCP-ALL cell lines were transduced with two different lentiviral constructs targeting CD19. A short hairpin RNA (shRNA) that specifically targets the fusion gene RUNX1/ETO without affecting endogenous RUNX1 was used as a control, 10 as this fusion is not found in any of the cell lines or primografts used (see Supplementary Methods for further details). We chose the pTRIPZ system, which allows doxycycline-mediated induction of shRNA) expression and puromycin selection of successfully transduced cells. Five days after induction, CD19 surface expression was reduced 15-fold in SEM cells, sixfold in REH cells and 14-fold in 697 cells by the best construct (shCD19II) compared to the geometric mean of expression in the control (Supplementary Figure 1) . The CD19 depletion was maintained over several time points (Supplementary Figure 2) . None of the cell lines showed any impairment in proliferation over 23-26 days (Figure 1a ) or doubling times: SEM (control: 34 h vs shCD19: 33 h), REH (control: 38 h vs shCD19: 34 h) and 697 (control: 30 h vs shCD19: 29 h). This suggests that, at the level of knockdown achieved, CD19 is not essential for the proliferation of BCP-ALL cell lines in suspension culture.
We next considered that CD19 could be important for niche interactions, so we used a murine stromal cell feeder layer to mimic this. Cells were grown on M2-10B4 cells in medium containing 2% fetal bovine serum, which was the level at which the SEM and 697 cells developed dependence on the feeder layer for growth at low cell densities (10 4 cells/ml) (Supplementary Figure 3) . REH cells did not develop feeder dependence to the same extent as the other cell lines. Next, we performed a competitive assay under these conditions. We seeded equal mixtures of transduced and un-transduced cell populations to determine whether CD19-depleted cells were at a competitive disadvantage to wild-type cells. The ratio of RFP + (shRNAexpressing) to RFP − (wild-type) cells was used to assess changes in the proportions of each population. We did not observe any substantial differences in the ratio of CD19 − to wild-type cells for any of the three cell lines studied (Figure 1b) , indicating that CD19 expression does not give cells a competitive growth advantage when adherent on stroma cells.
We also studied the effects of CD19 silencing in a high-risk pre-B-ALL t(17;19) primograft, L707, achieving a threefold reduction in Accepted article preview online 17 March 2016; advance online publication, 8 April 2016
